Health canada grants marketing authorization for trikafta® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in children with cystic fibrosis ages 6 through 11 years with at least one f508del mutation

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced that health canada has granted marketing authorization for the expanded use of trikafta® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include children with cystic fibrosis (cf) ages 6 through 11 years who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene. with this announcement, approximately 500 canadians with cf ages 6-11 are now eligible f
VRTX Ratings Summary
VRTX Quant Ranking